Pierre Legault has served as Chairman of the Board of Directors from March 2016 through March 2023. He has over 35 years of experience working in the pharmaceutical and biotechnology industry. Pierre Legault is also a director of Syndax Pharmaceuticals and Armo Biosciences. In the past, he was a director at Tobira Therapeutics, NPS Pharmaceuticals, Forest Laboratories, Regado Biosciences, Iroko Pharmaceuticals, Cyclacel Pharmaceuticals, Eckerd Pharmacy and NephroGenex, a biotechnology focused on kidney diseases, where he served from 2012 to 2016 as the Chairman and Chief Executive Officer. From 2010 to 2012, he served as the President and Chief Executive Officer of Prosidion Ltd., specialized in the treatment of diabetes and obesity. From 2009 to 2010, he served as the Executive Vice President, Chief Financial Officer and Treasurer of OSI Pharmaceuticals. Mr. Legault also served as the President of Eckerd Pharmacy and Senior Executive Vice - President of Rite Aid Corporation. Between 1989 and 2005, he held various roles, such as President, CEO and Chief Financial Officer, at legacy companies of the Sanofi-Aventis group. Mr. Legault holds an MBA in Marketing from McGill University and a bachelor’s degree from HEC (France). He also studied at Harvard Business School. He holds an MBA, BAA, CA, CPA and Six Sigma Green Belt diplomas.

Janice Bourque has served as a member of the Company's board of directors from January 2016 through March 2023. She has served as the Managing Director, Life Sciences of Hercules Technology Growth Capital Inc., a technology and life science specialty finance company, since 2010. From 2009 to 2010, Ms. Bourque served as a consultant for Commons Capital, where she advised and provided strategic corporate investor fund raising. From 2005 to 2009, she served as the Senior Vice President and Group Head-Life Sciences at Comerica Bank in Boston, Massachusetts. Ms. Bourque also held the position of President and Chief Executive Officer of the Massachusetts Biotechnology Council, the oldest biotechnology trade association in the world, where she was instrumental in its growth from 1992-2004. Ms. Bourque currently serves on the board of directors and audit committee of The Village Bank. Ms. Bourque holds a M.B.A. in Finance and Accounting from the University of New Hampshire and has a Bachelor of veterinary science degree.

Kumi Sato has served as a member of the Company's board of directors from June 2017 through March 2023. For over 30 years, Kumi Sato has served as President and CEO of Cosmo Public Relations Corporation, an award-winning strategic communications and public affairs firm based in Tokyo, Japan, with a specialized healthcare division, COSMO Healthcare. Since its founding, COSMO has consulted for over 500 companies in healthcare, food and food sciences, and the service industry. Before taking over as CEO in 1987, she founded COSMO International, which advised Japanese companies on US market entry strategies. During her time at COSMO, she has been instrumental in directing the company to broaden its international focus and has held a series of noteworthy advisor positions, such as President and Founder of Women Japan.com and Outside Director for Rokko & Associates Inc. In 2010, she founded BioCube, a think-tank to discuss Japan’s healthcare system and biotech-related topics. She currently serves as an advisor to the Global Health Innovative Technology Fund in Tokyo, a lecturer at the Graduate School of Business Breakthrough University and is Chairman Emeritus of the American Chamber of Commerce in Japan. In addition, she is co-chairman of the Global Council for the Asia Society, based in New York. Ms. Sato has also authored two business textbooks on communication strategies and corporate social responsibility. Ms Sato started her career at McKinsey & Co., New York and holds a B.A. in East Asian Studies from Wellesley College, MA.

John Kozarich served as a member of the Company's board of directors from June 2021 through June 2022. He has over 40 years of experience in the biopharmaceutical industry and academia. He is Distinguished Scientist Emeritus at ActivX Biosciences, Inc. (La Jolla, CA), an Adjunct Professor in the College of Pharmacy at the University of Texas, Austin. At ActivX, he was Chairman and President from 2004 to 2017 and served in senior management positions since 2001. Dr. Kozarich was Vice President at Merck Research Laboratories (1992-2001) where he was responsible for a variety of drug discovery and development programs and external biotech collaborations. Previously, he held full professorships at the University of Maryland and Yale School of Medicine. He was named a Director of the Year for 2014 by the Corporate Directors Forum for his work at Ligand Pharmaceuticals (LGND), has been an American Cancer Society Faculty Research Awardee, a recipient of the Pfizer Award in Enzyme Chemistry from the American Chemical Society (ACS), the Distinguished Scientist Award of the San Diego Section of the ACS and is a Fellow of the AAAS. Dr. Kozarich currently serves on the Boards of Ligand, Intec Pharma (NTEC) and Curza (Salt Lake City, UT). He holds a B.S. in chemistry from Boston College, a Ph.D. in biological chemistry from the Massachusetts Institute of Technology and was an NIH Postdoctoral Fellow at Harvard University.